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B Cell Activity Is Impaired in Human and Mouse Obesity and
Is Responsive to an Essential Fatty Acid upon Murine
Influenza Infection
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Obesity is associated with increased risk for infections and poor responses to vaccinations, which may be due to compromised B cell
function. However, there is limited information about the influence of obesity on B cell function and underlying factors thatmodulate
B cell responses. Therefore, we studied B cell cytokine secretion and/or Ab production across obesity models. In obese humans, B cell
IL-6 secretion was lowered and IgM levels were elevated upon ex vivo anti-BCR/TLR9 stimulation. In murine obesity induced by a
high fat diet, ex vivo IgM and IgG were elevated with unstimulated B cells. Furthermore, the high fat diet lowered bone marrow
B cell frequency accompanied by diminished transcripts of early lymphoid commitment markers. Murine B cell responses were
subsequently investigated upon influenza A/Puerto Rico/8/34 infection using a Western diet model in the absence or presence of
docosahexaenoic acid (DHA). DHA, an essential fatty acid with immunomodulatory properties, was tested because its plasma levels
are lowered in obesity. Relative to controls, mice consuming theWestern diet had diminished Ab titers whereas theWestern diet plus
DHA improved titers. Mechanistically, DHA did not directly target B cells to elevate Ab levels. Instead, DHA increased the concentration
of the downstream specialized proresolving lipid mediators (SPMs) 14-hydroxydocosahexaenoic acid, 17-hydroxydocosahexaenoic acid,
and protectin DX. All three SPMs were found to be effective in elevating murine Ab levels upon influenza infection. Collectively, the
results demonstrate that B cell responses are impaired across human and mouse obesity models and show that essential fatty acid status
is a factor influencing humoral immunity, potentially through an SPM-mediated mechanism. The Journal of Immunology, 2017, 198:
4738–4752.
O
besity is associated with impaired immunity, which
contributes toward a variety of comorbidities (1–4). Many
factors compromise innate and adaptive immunity in the
obese population, which include oxidative stress, hormonal im-
balances, and nutrient overload (5–7). A considerable amount of
work has defined the cellular and molecular mechanisms by
which obesity promotes an inflammatory profile, particularly in
adipose tissue (8, 9). In contrast, far less is known about how
obesity influences humoral immunity. This is an essential gap in
knowledge to address given that obesity is associated with in-
creased susceptibility to infections and poor responses to vac-
cinations (10–13).
There is some evidence that humoral immunity is impaired in
the obese, although there is no clear consensus. For example,
hemagglutination inhibition (HAI) titers, a standard assay used to
determine Ab levels to influenza virus, were reported normal 30 d
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Cells from peripheral blood were analyzed from nonobese (body mass
index [BMI], ,25 kg/m2) and obese (BMI, .30 kg/m2) male subjects
(Table I). The cohort included subjects who were nonsmokers with ex-
clusion criteria to be free of chronic inflammatory/autoimmune disease,
not taking supplements enriched in n-3 PUFAs, and free of infection
during the past month. Subjects were fasted overnight before obtaining
blood.
Peripheral blood taken in vacutainer tubes was diluted 1:1 in PBS fol-
lowed by separation of PBMCs using Ficoll Paque (GE Healthcare,
Washington, NC) gradient centrifugation. All fluorophore Ab markers used
were obtained from BioLegend (San Diego, CA) or Miltenyi Biotec (San
Diego, CA) and consisted of: Zombie NIR, CD45 (PE), CD3 (Pacific
Blue), CD4 (FITC), CD8 (PE-Cy5), CD14 (FITC), and CD19 (allophy-
cocyanin). Isolated PBMCs from gradient centrifugation were stained for
viability using Zombie NIR. The following subsets were analyzed using a
BD LSR II flow cytometer: CD45+CD3+CD4+, CD45+CD3+CD8+, CD45+
CD32CD14+, and CD45+CD142CD19+.
B cells were isolated from PBMCs using a B cell isolation kit II (Miltenyi
Biotec) with a resulting purity of .99%. Purified human B cells were
cultured in RPMI 1640 with 5% FBS, 2 mM L-glutamine, 5 3 1025 M 2-
ME, 10 mM HEPES, and 50 mg/ml gentamicin at a concentration of 3 3
106 cells/ml. B cells were stimulated with: 1) CpG oligodeoxynucleotide
(ODN) 2395 (a TLR9 agonist) at 1 mg/ml plus BCR stimulation using
rabbit anti-human IgM Ab fragment at a concentration of 2 mg/ml; 2)
Pam3CSK4 (a TLR1/2 agonist) at a concentration of 10 mg/ml. B cells
were plated in round-bottom inert grade 96-well plates and cultured in
duplicate for differing time points after activation. Supernatants IL-6, IL-
10, and TNF-a were measured on day 2 postactivation using Luminex
assay kits (Thermo Fisher Scientific) as per the manufacturer’s instruc-
tions. Supernatants IgM and IgG were measured on day 7 postactivation
using ELISAs (Abcam, Cambridge, MA) as per the manufacturer’s in-
structions.
Obesity mouse models
Murine experiments fulfilled the guidelines established by the East
Carolina University for euthanasia and humane treatment. Male C57BL/6
mice, ∼5–7 wk old, were fed experimental diets (Envigo, Indian-
apolis, IN) for 15 wk. In the first murine model, animals were fed a
control (10% of total kilocalories from lard) or HF diet (Research
Diets, New Brunswick, NJ) (60% of total kilocalories from fat) for 15
wk. In the second murine model, mice were fed a low fat control diet, a
WD, or a WD supplemented with DHA ethyl esters (Cayman Chemical,
Ann Arbor, MI) of .93% purity as previously described (39). The WD
provided 45% of total kilocalories from milk fat. DHA accounted for
2% of total energy, which is easily achievable for humans through
intake of over-the-counter or prescription supplements (40). The
composition of the experimental diets is provided in Supplemental
Table I.
Infection model
Animals were infected intranasally with 0.03 hemagglutinating unit (HAU)
of influenza A/PR/8/34 virus. All experiments with mice were in accor-
dance with the guidelines set forth by East Carolina University. Mice were
euthanized with CO2 inhalation followed by cervical dislocation. Tissues
were harvested following euthanasia.
SPM studies in vivo
SPMs were prepared as described (41). Six-week-old C57BL/6 mice (The
Jackson Laboratory, Bar Harbor, ME) were lightly anesthetized with iso-
flurane and then vaccinated with A/California/04/2009 (pdmH1N1) in the
absence or presence of 1 mg of D-series SPMs (Cayman Chemical). Three
weeks following vaccination, mice were bled and serum was analyzed for
HAI and microneutralization titers against pdmH1N1 virus. In other
studies, mice were given 1 mg of D-series SPMs in PBS/ethanol con-
comitant with 0.03 HAU of influenza A/PR/8/34 virus. PBS/ethanol alone
served as the vehicle control.
Metabolic studies
Mice were fasted for 6 h and the baseline glucose value was established
with a glucometer. An i.p. injection provided 2.5 g of dextrose (Hospira,
Lake Forest, IL) per kilogram of lean mass, and glucose measurements
were made from the tail vein. The homeostasis model assessment for
insulin resistance (HOMA-IR) index was calculated as previously de-
scribed (42). Echo-MRI was used as previously shown for fat/lean
mass (43).
postvaccination but were lowered 12 mo postvaccination in obese 
humans compared with nonobese subjects (13). In another study, 
the ability to mount influenza-specific IgM and IgG responses 8 
wk after influenza vaccination was normal in obese humans 
compared with lean controls, although the Ab response was di-
minished relative to an obese diabetic cohort (14). Mouse models 
also suggest that obesity impairs Ab production (15). For instance, 
murine HAI titers were lowered 7 d postinfection (p.i.) upon in-
fluenza infection and were completely blunted by 35 d p.i. (16). 
Moreover, the effects of obesity are not just limited to viral in-
fection because obese mice also have diminished Ab production 
upon Staphylococcus aureus infection (17).
There is strong evidence that B cells, which have a central role in 
humoral immunity, regulate adipose tissue inflammation in obesity 
(18–21). For instance, in obese mice, IgG2c is elevated in adipose 
tissue and the B regulatory/B1 subsets improve adipose tissue 
inflammation (22–25). In contrast, much less is known about the 
influence of obesity on B cell cytokine secretion and Ab pro-
duction outside of the context of adipose tissue inflammation (26). 
There are some conflicting reports suggesting that B cell activity 
could be impaired with type 2 diabetes, a comorbidity associated 
with obesity (20, 27). In obese type 2 diabetic mice, B cells se-
crete proinflammatory cytokines, similar to diabetic and/or obese 
patients with elevated fasting glucose (20, 28). Alternatively, 
newly diagnosed patients with diabetes have suppressed B cell 
inflammatory cytokines upon stimulation whereas Ab production 
is reported to be normal upon influenza vaccination (27, 29).
If B cell function is potentially compromised in the obese, then it is 
essential to define those factors that modulate B cell activity. Es-
sential fatty acid status is a neglected variable in studies of humoral 
immunity. Essential n-3 polyunsaturated fatty acids (PUFAs) are of 
interest given their immunomodulatory properties (30). Further-
more, plasma levels of long-chain n-3 PUFAs are low in obese 
individuals compared with lean controls, which could contribute 
toward impairments in humoral immunity (31–33). The two major 
long-chain n-3 PUFAs of interest are eicosapentaenoic and doco-
sahexaenoic acids (DHA), which can have anti-inflammatory effects 
but their influence on B cell activity is far less known (30). Our 
laboratory, in addition to other investigators, has recently discovered 
that n-3 PUFAs, particularly DHA, may improve B cell–driven 
responses, warranting more in-depth studies (34, 35).
The objectives of this study were to investigate whether obesity 
impairs B cell responses across three models and whether essential 
fatty acid status has a role in modulating Ab levels. B cell cytokine 
secretion and Ab production upon ex vivo stimulation were first 
investigated in a cohort of obese humans relative to lean controls. We 
next examined whether a high fat (HF) diet–induced model of 
obesity impaired murine ex vivo Ab production and B cell fre-
quency in the bone marrow. Subsequently, the effects of a murine 
Western diet (WD) model (that provides moderate levels of fat) in 
the absence or presence of DHA was tested on Ab responses to 
influenza infection. Influenza infection, which allowed for the 
stimulation of B cells in vivo, is a significant burden in the obese 
population (4, 36). Finally, selected mechanistic underpinnings by 
which DHA could improve primary B cell responses in obese mice 
upon influenza infection were investigated. We focused on down-
stream D-series–specialized proresolving lipid mediators (SPMs) 
that have potent immune-enhancing properties on B cells (37, 38).
Materials and Methods
Human subjects and PBMC/B cell analyses
Human blood samples were procured after informed consent and under 
approval by the East Carolina University Institutional Review Board.
PCRs
Quantitative RT-PCR analysis was conducted on total bone marrow cells
and B cells as previously described (39). The fold change from the control
was calculated by the 22DDCt method. Primer sequences used in the study
are provided in Supplemental Table II. For PCR analyses, total RNA was
isolated from sorted splenic B220+ cells using a B220+ FITC (BioLegend)
Ab. cDNA (0.5 mg) was synthesized using a first-strand synthesis kit
(Invitrogen, Carlsbad, CA). Both random hexamer and oligonucleotide
primers were used in the reaction. Following synthesis of cDNA, PCR was
conducted in a 50-ml reaction mix using Platinum PCR SuperMix High
Fidelity (Invitrogen). A 300 nM concentration of primer solutions was
used followed by the addition of cDNA. PCR products were visualized on
a 1% agarose gel.
Flow cytometry
Bone marrow was extracted as previously demonstrated (39). For con-
sistency, the left leg was used for each mouse. The fluorescently labeled
Abs were obtained from BioLegend and consisted of CD19 (PerCP-
Cy5.5), CD43 (allophycocyanin), CD24 (Pacific Blue), IgM (PE),
IgD (allophycocyanin), and CD138 (allophycocyanin). The following
B cell subsets were analyzed: CD192CD43+CD242IgM2 (prepro),
CD19+CD43+CD24+IgM2 (pro), CD19+CD432CD24+IgM2 (pre),
CD19+CD24+IgM+IgD2 (immature), CD19+IgM+IgD+ (mature), and
CD19+CD138+ (plasma cells).
ELISAs, HAI, and microneutralization assays
IgM and IgG levels (Abcam) were analyzed from serum with ELISAs (34).
For the HAI assay, serum was treated overnight with receptor-destroying
enzyme (RDE; Denka Seiken, Campbell, CA), followed by heat inacti-
vation for 1 h and then diluted 1:10 in PBS (16). HAI assays were per-
formed according to World Health Organization guidelines (Global
Influenza Surveillance Network Manual for the laboratory diagnosis and
virological surveillance of influenza). RDE-treated sera were incubated
with 4 HAU of influenza virus for 15 min at room temperature followed by
a 1-h incubation at 4˚C with 0.5% turkey RBCs. HAI was calculated by
taking the reciprocal of the highest dilution of serum that completely
inhibited hemagglutination of the turkey RBCs (16).
For microneutralization assays, RDE-treated sera were diluted in
microneutralization media (DMEM, 2 mM glutamine, 1% BSA) at a 1:2
dilution. Sera were then incubated with 100 tissue culture-infective dose
(50%) virus for 1 h at 37˚C on white polystyrene plates. Following incu-
bation, 3 3 104 Madin–Darby canine kidney cells were added to each well
and plates were incubated at 37˚C overnight. The bulk of the media was
removed and plates were frozen for at least 30 min at 280˚C. Lumines-
cence was determined by adding 25 ml of Nano-Glo substrate solution
(Promega) according to the manufacturer’s instructions, and the plates
were placed in a Synergy H1 hybrid reader. Neutralization was considered
to be any well below half the luminescence generated by a well infected
with 100 tissue culture-infective dose (50%) A/Puerto Rico/8/34 NLuc
virus (44).
Lipidomic sample preparation
All standards and internal standards used for liquid chromatography–
tandem mass spectrometry analysis were purchased from Cayman Chemical.
All solvents were HPLC grade or better. Tissue homogenate samples were
pretreated for solid phase extraction as follows. Briefly, a volume of tissue
homogenate equivalent to 500 mg was brought to a volume of 1 ml in 10%
methanol along with 10 ml of 10 pg/ml internal standard solution [100 pg
total per each of 5(S)-HETE-d8, 8-iso-PGF2a-d4, 9(S)-HODE-d4, LTB4-d4,
LTD4-d5, LTE4-d5, PGE2-d4, PGF2a-d9, and RvD2-d5 in ethanol].
Serum samples were pretreated for solid phase extraction. Proteins were
precipitated from 50 ml of serum by adding 200 ml of ice-cold methanol
and 10 ml of the internal standard solution, followed by vortexing and then
incubating on ice for 15 min. The samples were then placed in a micro-
centrifuge for 10 min at 4˚C at 14,000 rpm. A 200-ml portion of the su-
pernatant was diluted to 10% methanol by adding 1.4 ml of water. Lipid
mediators were isolated from the pretreated samples by solid phase ex-
traction as described (45). Lipid mediators were extracted using Strata-X
33-mm 30 mg/1 ml SPE columns (Phenomenex, Torrance, CA) on a
Biotage positive pressure SPE manifold. Columns were washed with 2 ml
of methanol followed by 2 ml of H2O. After applying the sample, the
columns were washed with 1 ml of 10% methanol and the lipid mediators
were then eluted with 1 ml of methanol directly into a reduced surface
activity/maximum recovery glass autosampler vial. The methanol solvent
was then evaporated to dryness under a steady stream of nitrogen directly
on the SPE manifold. The sample was immediately reconstituted with
15–20 ml of ethanol and analyzed immediately or stored at 270˚C until
analysis for #1 wk.
Lipid mediators in whole spleen samples were isolated as described by
Yang et al. (46). Spleen samples were preweighed and transferred into a
1.5-ml microcentrifuge tube. One microliter of methanol and 10 ml of
internal standard solution were added and then the sample was vortexed
and stored overnight at 220˚C. The sample was transferred to a DUALL
all-glass size 21 tissue homogenizer and ground until completely ho-
mogenized. The homogenate was transferred to a 1.5-ml centrifuge tube
and centrifuged at 14,000 rpm for 10 min at 4˚C. The supernatant was
diluted to 10 ml with water adjusted to pH 3.5. The samples were then
applied to HyperSep C18 500 mg/6 ml SPE columns (Thermo Fisher
Scientific) that were prewashed with 20 ml of methanol followed by 20 ml
of water. The SPE columns were washed with 10 ml of water followed by
10 ml of hexane. Lipid mediators were eluted with 8 ml of methyl formate
(eicosanoids and docosanoid fraction) followed by 10 ml of methanol
(cysteinyl leukotriene fraction). Both fractions were dried under a stream
of nitrogen and reconstituted with ethanol and combined into a reduced
surface activity/maximum recovery glass autosampler vial analyzed im-
mediately or stored at 270˚C until analysis for #1 wk.
Liquid chromatography–mass spectrometry
Quantitation of lipid mediators was performed using two-dimensional re-
verse phase HPLC tandem mass spectrometry (liquid chromatography–
tandem mass spectrometry). The HPLC system consisted of an Agilent
1260 autosampler (Agilent Technologies, Santa Clara, CA), an Agilent
1260 binary loading pump (pump 1), an Agilent 1260 binary analytical
pump (pump 2), and a six-port switching valve. Pump 1 buffers consisted
of 0.1% formic acid in water (solvent A) and 9:1 v/v acetonitrile/water
with 0.1% formic acid (solvent B). Pump 2 buffers consisted of 0.01%
formic acid in water (solvent C) and 1:1 v/v acetonitrile/isopropanol
(solvent D).
Ten microliters of extracted sample was injected onto an Agilent SB-C18
2.13 5 mm, 1.8-mm trapping column using pump 1 at 2 ml/min for 0.5 min
with a solvent composition of 97% solvent A/3% solvent B. At 0.51 min
the switching valve changed the flow to the trapping column from pump 1 to
pump 2. The flow was reversed and the trapped lipid mediators were
eluted onto an Agilent Eclipse Plus C18 2.1 3 150 mm, 1.8-mm analytical
column using the following gradient at a flow rate of 0.3 ml/min: hold at
75% solvent A/25% solvent D from 0 to 0.5 min, then a linear gradient
from 25 to 75% D during 20 min followed by an increase from 75 to
100% D from 20 to 21 min, then holding at 100% D for 2 min. During the
analytical gradient, pump 1 washed the injection loop with 100% B for
22.5 min at 0.2 ml/min. Both the trapping column and the analytical
column were re-equilibrated at starting conditions for 5 min before the
next injection.
Mass spectrometric analysis was performed on an Agilent 6490 triple
quadrupole mass spectrometer in negative ionization mode. The drying
gas was 250˚C at a flow rate of 15 ml/min. The sheath gas was 350˚C at
12 ml/min. The nebulizer pressure was 35 psi. The capillary voltage was
3500 V. Data for lipid mediators was acquired in dynamic MRM mode
using experimentally optimized collision energies obtained by flow in-
jection analysis of authentic standards. Calibration standards for each lipid
mediator were analyzed over a range of concentrations from 0.25 to 250 pg
on column. Calibration curves for each lipid mediator were constructed
using Agilent MassHunter quantitative analysis software. Tissue and serum
samples were quantitated using the calibration curves to obtain the column
concentration, followed by multiplication of the results by the appropriate
dilution factor to obtain the concentration in picograms per microgram of
protein (tissue homogenates) or picograms per milliliter (serum).
Proliferation assays
B cell pellets were stored for a minimum of 24 h at 280˚C. A
CyQUANT cell proliferation assay kit (Molecular Probes, Eugene, OR)
was used to quantify number of cells per well and as per the manufac-
turer’s instructions.
In vitro studies
Mouse splenic B cells were plated in 96-well plates at 1 3 106/ml and
activated with: 1) 1 mg/ml CpG 1826 (Novus Biologicals, Littleton, CO)
plus 2 mg/ml anti-IgM (Jackson ImmunoResearch Laboratories, West
Baltimore Pike, PA), or 2) 1 mg/ml LPS (Sigma-Aldrich, St. Louis, MO).
Cells were also treated with 5 mM rosiglitazone (Sigma-Aldrich) or 5 mM
DHA (Cayman Chemical) and then activated 30 min later with 1 mg/ml
CpG 1826 plus 2 mg/ml anti-IgM. DHA stocks were conjugated to BSA as
previously described (47).
secretion and Ab production upon CpG-ODN plus anti-IgM
stimulation.
B cell IgM and IgG levels are elevated in the absence of
stimulation for mice consuming an HF diet
Experiments were next conducted in a mouse model to determine
whether murine B cell activity was also impaired in response to
diet-induced obesity. Ex vivo splenic B cell Ab production was
measured using lean and HF diets. Mice consuming the HF diet
displayed elevated levels of ex vivo IgM (Fig. 2A, left panel) and
IgG (Fig. 2B, left panel) in the absence of stimulation. There was
no absolute change in IgM (Fig. 2A, left panel) or IgG (Fig. 2B,
left panel) production with the HF diet upon stimulation with
either CpG-ODN plus anti-IgM or LPS. However, relative to the
negative controls, the increase in IgM (Fig. 2A, right panel) and
IgG (Fig. 2B, right panel) levels for obese mice upon stimulation
with either CpG-ODN plus anti-IgM or LPS were diminished by
$2-fold relative to the control mice. Circulating IgM (Fig. 2C, left
panel) and IgG (Fig. 2C, right panel) levels were also assayed and
there was a significant increase in the levels of IgG with obese
mice.
The frequency of bone marrow B cell subsets is lowered in mice
consuming an HF diet
In parallel with the ex vivo studies, we probed for potential defects
in B cell development (Fig. 3). The percentage (Fig. 3A, left panel)
and frequency (Fig. 3A, right panel) of B cells in the bone marrow
were lowered with the HF diet relative to the lean control by ∼2-
fold. B cell subsets were further analyzed with flow cytometry
(Fig. 3B). There was attenuation in the percentage of CD19+IgM2
CD432CD24+ cells with mice consuming the HF diet compared
with the control (Fig. 3C, left panel). The frequency of all the
major B cell subsets was lowered with the HF diet relative to the
control (Fig. 3C, right panel). Additionally, CD138+ B cells were
analyzed by flow cytometry (Fig. 3D). The percentage (Fig. 3E,
left panel) and frequency (Fig. 3E, right panel) of CD138+ B cells
in the bone marrow were lowered with the HF diet compared with
the control by 1.7- to 2-fold. B cell proliferation was not influ-
enced by the HF diet relative to the lean control (data not shown).
Table I. Patient characteristics
Parameters Nonobese (n = 10) Obese (n = 10)
Age (y; mean and range) 34.54 (22–57) 37.63 (22–65)
BMI (kg/m2; mean and range) 24.0 (21.7–28.8) 39.6 (30.0–65.7)****
Race, n (%)
White 9 (90%) 7 (70%)
African American — 3 (30%)
Indian 1 (10%) —
Medications, n (%)
NSAID 1 (10%) —
PDE5 inhibitor 1 (10%) —
Phenethylamine 1 (10%) —
SSRI 1 (10%) 1 (10%)
Vitamin 1 (10%) —
Benzodiazepine — 3 (30%)
b Blocker — 1 (10%)
Cyclopyrrolone — 1 (10%)
HMG CoA reductase inhibitor — 1 (10%)
Proton pump inhibitor — 3 (30%)
Sulfonylurea — 1 (10%)
Testosterone — 1 (10%)
The subject who consumed nonsteroidal anti-inflammatory drug does not have a chronic inflammatory condition. Dash (—)
indicates not applicable.
****p , 0.0001.
NSAID, nonsteroidal anti-inflammatory drug; SSRI, selective serotonin reuptake inhibitor.
Statistical analysis
All murine results are from multiple cohorts of mice. Data were analyzed 
with GraphPad Prism version 5.0b. IgM and IgG levels assayed in human 
studies were fit using linear regression analysis. Most data sets displayed 
normalized distributions as determined by a Kolmogorov–Smirnov test. 
Statistical significance for human studies, in vitro experiments, and those 
experiments comparing lean versus HF-fed mice were analyzed with a 
two-tailed unpaired Student t test. All other analyses relied on one-way or 
two-way ANOVAs followed by a post hoc Bonferroni multiple comparison 
tests. Those data sets that did not display normalized distributions were 
analyzed with a Kruskal–Wallis test followed by a Dunn multiple com-
parison test. A p value of ,0.05 was considered significant.
Results
B cell IL-6 secretion is lowered and IgM levels are elevated in 
obese humans
We first studied B cell responses in a cohort of age-matched 
nonobese and obese males that considerably differed in BMI 
(Table I). Flow cytometry analysis of PBMCs (Fig. 1A) generally 
revealed an increased percentage of B cells (p = 0.05) in obese 
individuals with no effect on monocytes, CD4+ cells, or CD8+ 
T cells (Fig. 1B). When B cells were enumerated with trypan blue 
exclusion upon purification of the cells, there was a significant 
increase in B cell frequency in the obese subjects compared with 
nonobese controls (Fig. 1C).
Highly purified B cells, as assessed by CD14 and CD19 staining 
(Fig. 1D), were used for measuring cytokine and Ab production. 
IL-6 secretion in response to activation with CpG-ODN  (TLR9
agonist) plus anti-IgM (for BCR engagement) was ∼35–40%
lower in B cells from obese relative to nonobese subjects with no 
significant effect on TNF-a or IL-10 secretion (Fig. 1E, left 
panel). B cell cytokine secretion from obese subjects was not 
affected upon targeting of TLR1/2 with Pam3CSK4 relative to 
controls (Fig. 1E, right panel). Cytokine secretion was not de-
tectable in the absence of CpG-ODN plus anti-IgM or Pam3CSK4 
stimulation (data not shown). Activation of B cells with CpG-
ODN plus anti-IgM revealed a correlation between increasing 
IgM levels (Fig. 1F) and increasing BMI, with no correlation 
between IgG levels and BMI (Fig. 1G). Thus, the studies with 
human subjects showed obesity dysregulated B cell cytokine
To explain the reduction in the proportion of B cells in the
bone marrow, selected markers relevant to early lymphoid
commitment were assayed at the mRNA level from isolated bone
marrow cells (Fig. 3F). We specifically focused on the early
lymphoid commitment markers IL-7Ra, IL-7, and STAT5
(Fig. 3F) (48, 49). With mice consuming the HF diet relative to
lean controls, bone marrow transcripts of IL-7Ra and IL-7 were
decreased by ∼2-fold, whereas STAT5 showed a trend toward
being lowered (p = 0.08). Markers of intermediate (PAX5 and
OCT2) and late B cell development (Blimp1) were also assayed
(50, 51). These markers, which may reflect the decrease in
B cell subset frequency, were also lowered by $2-fold in the
bone marrow of mice on an HF diet compared with controls
(Fig. 3F).
FIGURE 1. B cell IL-6 secretion and IgM production are modified in human obesity. (A) Sample flow cytometry data showing the percentage of B
cells, monocytes, helper CD4+ cells, and cytotoxic CD8+ T cells in PBMCs. (B) Quantification of the percentage of CD45+ cells in PBMCs. (C)
Frequency of B cells isolated via negative selection from nonobese and obese subjects and enumerated with trypan blue exclusion. (D) Purity of B cells
as measured by CD19/CD14 staining with flow cytometry. (E) B cell cytokine secretion upon CpG-ODN plus anti-IgM or Pam3CSK4 stimulation.
Correlation plots of (F) IgM and (G) IgG upon stimulation with CpG-ODN plus anti-IgM with BMI. Data are average 6 SEM; n = 10 nonobese and 10
obese subjects for (B) and (D) and n = 16 subjects for (F) and (G). *p , 0.05, by unpaired Student t test (B, C, and E). Correlation plots (F and G) relied
on linear regression analyses.
The next set of studies focused on how amoderateWDmodel in the
absence or presence of DHA would influence primary B cell re-
sponses, which was assayed in response to a mouse-adapted in-
fluenza stain (18). DHA was specifically used because essential
fatty acid levels are lowered in obesity (31). The composition of
the diets was routinely verified to ensure the absence of DHA in
the WD compared with WD plus DHA and diets were also con-
tinuously monitored for the lack of oxidation prior to and during
the course of the study (data not shown). Prior to infection, body
weights were elevated for both WDs compared with the control
(Fig. 4A), which was driven by an increase in fat mass and not
lean mass (Fig. 4B). The HOMA-IR index, a measure of glucose/
insulin sensitivity, was elevated for mice fed both WDs relative to
the lean mice (Fig. 4C).
Infection studies revealed that on day 7 p.i., the WD fed mice
tended to have lower HAI titers, similar in magnitude to those
found in a previous report (16). Inclusion of DHA in the diet in-
creased the HAI titers relative to the WD by 4-fold (Fig. 4D). HAI
titers were not assessed on day 14 p.i. given that mice consuming a
WD show no impairment in Ab production at this time point (16).
Notably, on day 7 p.i., only 66% of the mice consuming the WD
had measurable HAI titers (Fig. 4E), consistent with previous
work (16). On day 21 p.i., HAI titers were lowered in mice fed the
WD by ∼43% compared with the lean control (Fig. 4D). DHA
improved the titers compared with the WD by 25% but not to the
same level as the control (Fig. 4D). Given that DHA showed a
modest effect on HAI titers at 21 d p.i., we further investigated
using a microneutralization assay. This assay revealed that the
WD lowered titers (p = 0.06) by 2.6-fold relative to the lean
control and that the inclusion of DHA in the diet improved titers
by 3.7-fold relative to WD (Fig. 4F).
Recovery of the mice in response to the infection was also
measured. Mice consuming the WD did not have a significant
difference in recovery, as measured by the total loss of body mass,
compared with the control diet in the early part of the time course;
however, on day 14 p.i. the body mass of mice on the WD was
significantly lower compared with the control and WD plus DHA
(Fig. 4G). When calculated as the percentage weight loss, the WD
plus DHA modestly improved recovery relative to the WD at days
7–10 p.i. (Fig. 4H). The results from this model further established
compromised B cell responses with obesity and highlighted the
importance of DHA status.
DHA is not directly targeting B cells, suggesting a role for
downstream SPMs
The next objective was to establish how DHA could enhance Ab
titers. We first focused on DHA binding the G protein–coupled
receptor (GPR)120, a sensor for DHA reported to be on the sur-
face of macrophages but not investigated with B cells (52). PCR
analysis of sorted B cells showed very low abundance of GPR120
compared with epididymal adipose tissue, and activation of
B cells with GPR120 agonists did not promote Ab production
(data not shown).
A second possibility was DHA directly targeting B cells to
increase Ab levels, potentially by binding peroxisome proliferator–
activated receptor (PPAR)g. Activation of B cell PPARg with
agonists boosts Ab levels in human B cells although less is known
about mouse B cells (53). Thus, to first determine that PPARg
activation promotes Ab production in mouse cells, splenic B cells
were pretreated with 5 mM rosiglitazone, a PPARg agonist.
Stimulation in the presence of rosiglitazone with CpG-ODN plus
anti-IgM increased IgG but not IgM levels after 3 d (Supplemental
Fig. 1A) and both IgM and IgG were elevated after 6 d
(Supplemental Fig. 1A). The increase in Ab levels was not driven
by an increase in the proliferation of the B cells (Supplemental
Fig. 1B) as reported for human B cells (53). Given that PPARg
stimulation enhanced Ab production in mouse B cells, we next
tested the effects of in vitro treatment with DHA, a known PPARg
agonist. When B cells were treated with 5 mM DHA for 3 d, IgM
and IgG levels were dramatically lowered (Fig. 5A) in parallel
with a decrease in B cell proliferation (Fig. 5B) compared with a
FIGURE 2. B cell IgM and IgG levels are elevated in the 
absence of stimulation with mice consuming HF diets. (A)
IgM and (B) IgG levels from splenic B cells in the absence
and presence of CpG-ODN plus anti-IgM or LPS stimula-
tion are shown. Fold changes in IgM and IgG relative to the 
negative control are depicted to the right. Ex vivo antibody 
levels were measured on day 3 postactivation. Circulating
(C) IgM and IgG levels for mice consuming a lean control
or HF diet are shown. Mice were fed experimental diets
for 15 wk. Data are average 6 SEM; n = 6–7 mice per diet.
*p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001, by 
unpaired Student t test.
The Ab response is decreased in a murine WD model and 
improved by DHA upon influenza infection
BSA control. This ruled out that DHA was having a direct effect
on the B cells as a PPARg agonist. Conversely, the results sug-
gested that DHA by itself lowered B cell proliferation and activity.
We then tested the possibility that D-series SPMs synthesized
from DHA could boost Ab production (Fig. 5C). The SPM 17-
hydroxydocosahexaenoic acid (HDHA) is reported to increase Ab
levels in vitro and in a preclinical model of vaccination (41, 54).
Given that DHA would likely give rise to multiple SPMs in vivo,
several D-series SPMs downstream of 17-HDHA were tested.
We used a preclinical vaccination model used for 17-HDHA to
directly compare our results (54). HAI titers (Fig. 5D) were
significantly elevated, compared with the vehicle control, with
resolvin (Rv)D1, RvD2, and protectin DX (PDX). Micro-
neutralization titers revealed a similar trend with the exception
of RvD2 in boosting Ab levels (Fig. 5E).
We confirmed that B cells express multiple receptors that could
respond to differing SPMs (Fig. 5F). Sorted splenic and bone
marrow B cells expressed the SPM receptors ALX/FPR2 and
ChemR23 at the mRNA level (Fig. 5G). In comparison, transcript
levels of BLT1, the receptor for LTB4 and RvE1, was robustly
expressed at the mRNA level in B cells (Fig. 5G). Splenic B cell
transcripts of ALX/FPR2 and ChemR23 were notably lower than
peritoneal macrophages, which were used as a control because
they expressed high levels of the SPM receptors (37).
DHA increases D-series SPMs in the WD model accompanied
by an increase in the frequency of CD138+ cells
The next set of experiments tested the possibility that DHAwould
increase downstream SPMs in mice consuming the WD at 7 d p.i.
Lipid mediators (Fig. 6A–D) were first assayed in serum to assess
circulatory levels. SPMs were not significantly elevated in serum
in response to DHA in the diet (Fig. 6E). Because there is debate
as to whether SPMs are measurable in circulation (55, 56), levels
of D-series SPMs were also measured in the spleen. In the spleen,
the WD plus DHA increased the levels of 14-HDHA and 17-
HDHA by up to 2-fold compared with the WD and/or the control
FIGURE 3. The frequency of bone marrow B cell subsets is lowered in mice consuming an HF diet accompanied by diminished early lymphoid
commitment markers. (A) Percentage and frequency of total B cells in the bone marrow of mice consuming control and HF diets. (B) Sample gating strategy
for analyzing B cell subsets in the bone marrow. (C) Percentage and frequency of B cell subsets in the bone marrow. (D) Sample gating strategy for
analyzing CD138+ B cells in the bone marrow. (E) Percentage and frequency of CD138+ B cells for lean and obese mice. (F) Transcript levels of key early,
intermediate, and late B cell development markers assayed on total bone marrow cells. Mice were fed a control or an HF diet for 15 wk. Data are average6
SEM; n = 5–7 mice per diet for (A), (C), and (E) and 10–11 mice per diet for (F). *p , 0.05, **p , 0.01, ***p , 0.001, by unpaired Student t test.
(Fig. 6F). PDX levels were lowered by 50% with the WD com-
pared with the control. RvD2 levels trended (p = 0.07) in a
downward fashion with the WD compared with the control
(Fig. 6F). PDX and RvD2 levels were generally restored to control
levels with WD plus DHA (Fig. 6F). The increase in D-series
SPMs, particularly in spleen, were accompanied by a reduction
in a range of n-6 PUFA-derived mediators, notably those derived
from arachidonic acid (Supplemental Fig. 2A, 2B) with some
additional changes in linoleic acid–derived mediators with both
WDs (Supplemental Fig. 2C, 2D).
Because 17-HDHA is reported to increase Ab production by
increasing the frequency of bone marrow CD19+CD138+ plasma
cells (41, 54), and DHA elevated 17-HDHA, we determined
whether DHA elevated the production of CD19+CD138+ cells at
day 21 p.i. The frequency of B cells was slightly lowered by the
WD relative to the control (Fig. 7A). There was no change in the
percentage (Fig. 7B, left panel) or frequency (Fig. 7B, right panel)
of the major B cell subsets with either WD. Upon flow cytometry
analysis of the CD138+ population (Fig. 7C), the WD diet tended
(p = 0.07) to lower the percentage of CD138+ cells relative to the
control (Fig. 7D, left panel). The percentage (Fig. 7D, left panel)
and frequency (Fig. 7D, right panel) of CD138+ cells increased
with the WD plus DHA compared with the WD. Thus, the phe-
notyping data revealed that DHA enhanced the frequency of
CD138+ cells in the bone marrow, further suggesting a mechanism
mediated by 17-HDHA (41, 54).
Administration of D-series SPMs after infection boosts Ab
titers
The next set of experiments tested the possibility that 17-HDHA
and perhaps other D-series SPMs would boost Ab titers. Mice were
injected with 17-HDHA 24 h after the administration of the in-
fluenza virus and Ab titers were assayed at 14 d p.i. Given that the
lipidomic data showed DHA elevated 14-HDHA and PDX, these
molecules were also specifically tested. HAI (Fig. 8A, left panel)
and microneutralization (Fig. 8A, right panel) titers were elevated
FIGURE 4. AWD suppresses Ab titers, which are improved with the essential fatty acid DHA. (A) Body weights of mice prior to infection after 15 wk of
dietary intervention. (B) Lean and fat mass as measured by Echo-MRI. (C) HOMA-IR index calculated from fasting glucose/insulin. Mice were fasted for
6 h prior to measurements. (D) HAI titers for C57BL/6 mice that were fed a control, WD, or WD plus DHA diets for 15 wk followed by influenza infection.
(E) Percentage of mice showing HAI Abs at day 7 p.i. (F) Microneutralization titers for C57BL/6 mice that were fed a control, WD, or WD plus DHA diets
for 15 wk followed by influenza infection for 21 d. (G) Absolute weight loss and (H) percentage weight loss as a function of time are shown. Data are
average 6 SEM; n = 4–9 mice per diet for (A)–(F) and 15–20 mice per diet for (G) and (H). *p , 0.05, **p , 0.01, ***p , 0.001, by one-way ANOVA
followed by a Bonferroni posttest (A, B, C, and F) or a two-way ANOVA followed by a Bonferroni posttest (D, G, and H).
with 14-HDHA, 17-HDHA, and PDX. Body weight analysis
during the course of the infection showed no effect of 14-HDHA,
17-HDHA, or PDX on murine recovery compared with the vehicle
control (data not shown).
14-HDHA administered with infection enhances Ab titers
accompanied by an increase in the frequency of CD138+ cells
We finally tested whether administration of the three SPMs had the
same effect when administered in parallel with the infection.
Surprisingly, HAI (Fig. 8B, left panel) and microneutralization
(Fig. 8B, right panel) titers were only elevated with 14-HDHA, but
not 17-HDHA or PDX. We further probed whether 14-HDHAwas
selectively promoting the production of CD138+ cells in the bone
marrow at day 21 p.i. (Fig. 8C). Flow cytometry analyses revealed
a $2-fold elevation in the percentage (Fig. 8D, left panel) and
frequency (Fig. 8D, right panel) of CD138+ cells with 14-HDHA
but no effect of 17-HDHA or PDX. Thus, these results showed
that SPMs have differing effects on Ab production depending on
the time of the administration and, notably, 14-HDHA increased
Ab levels accompanied by an increase in CD138+ cells.
Discussion
B cell activity is modified across obesity models
The results of our study demonstrate that B cell cytokine secretion
and/or Ab production are modified across mouse and human
obesity models. Few studies in humans have directly investigated
whether B cell function is impaired with obesity; therefore, this was
first addressed by testing how ex vivo B cell cytokine secretion and
Ab production were influenced in obese subjects. Notably, IL-6
secretion was lowered upon BCR/TLR9 activation, which agrees
with a report revealing that B cell cytokine secretion can be
suppressed in early stage patients with diabetes (27). However,
the cytokine data were not in complete agreement with results
FIGURE 5. DHA is not directly targeting B cells to boost Ab production, suggesting a role for D-series SPMs. (A) IgM and IgG levels upon treatment of
splenic B cells with 5 mM DHA. DHA was added 30 min prior to activation with CpG-ODN plus anti-IgM and was further added each day for 3 d. BSA
served as a control because DHAwas complexed to BSA. (B) Proliferation of B cells in response to DHA treatment. (C) Pathway by which DHA promotes
production of downstream SPMs. LOX is for lipoxygenase. (D) HAI and (E) microneutralization titers of mice after vaccination with pdmH1N1 vaccine in
response to vehicle control or SPM injection. (F) Sample PCR data showing mRNA expression of ALX/FPR2, ChemR23, and BLT1 for sorted splenic and
bone marrow B cells. Peritoneal macrophages were used for comparative purposes. (G) Quantification of mRNA expression of ALX/FPR2, ChemR23, and
BLT1. Data are average 6 SEM; n = 3–5 independent experiments except (F), which is a single experiment representative of three independent experi-
ments. *p, 0.05, **p, 0.01, ***p, 0.001, by unpaired Student t test (A) or two-way ANOVA followed by a Bonferroni posttest (B), or a Kruskal–Wallis
test followed by a Dunn multiple comparison test (D and E).
showing that LPS enhances some proinflammatory cytokines in
obesity from human or mouse B cells upon ex vivo stimulation
(28). We hypothesize that this is likely driven by differences in
signaling pathways (i.e., TLR4 compared with BCR/TLR9), and
our human subjects were mostly free of a diagnosis of type 2
diabetes and therefore may not display elevated B cell cytokines.
An additional finding with human subjects was an increase in the
frequency of B cells, which was consistent with data showing an
enhanced percentage of B cells in obese and type 2 diabetic pa-
tients (14).
The human and mouse models of obesity revealed several
changes in B cell Ab production. In humans, IgM but not IgG levels
positively correlated with increasing BMI upon BCR/TLR9
stimulation. In contrast, the HF diet elevated murine IgM and
IgG levels prior to BCR/TLR9 stimulation, suggesting hyper-
stimulated B cells that did not respond efficiently to BCR/TLR9 or
TLR4 stimulation when comparing Ab levels between the stim-
ulated and unstimulated conditions. This result supports the
emerging notion that hyperstimulated B cells function sub-
optimally (20, 57). The differences in Ab production between the
human and mouse data were not entirely surprising given differing
model systems. One clear set of distinctions between mice and
humans was that diet was not controlled for in the human studies
and the human population is genetically diverse. Future studies
FIGURE 6. DHA enhances downstream D-series SPM levels of mice consuming a WD. Extracted ion chromatograms (A and C) and product ion spectra
(B and D) for 10(S),17(S)-DiHDoHE (PDX) in mouse serum (A and B) and authentic standard (C and D) are shown. Specialized proresolving lipid mediators
synthesized from DHA in murine (E) serum and (F) spleen at 7 d p.i. upon consuming a control, WD, or WD plus DHA for 15 wk. n = 5–10 mice per diet.
Samples for serum analyses required the pooling of two mice per experiment. *p , 0.05, **p , 0.01, ***p , 0.001, by one-way ANOVA followed by a
Bonferroni posttest.
will need to address differences in B cell responses between
mouse and human models.
The mechanisms by which obesity impairs B cell production of
Ab are likely pleiotropic. Upon affinity maturation, B cells dif-
ferentiate into plasma cells that are responsible for secretion of
high-affinity class-switched Abs, which are essential for prolonged
protective immunity. In the HF diet model, there was a clear re-
duction in the percentage of bone marrow CD138+ B cells, and a
similar trend was observed in the WD model. Furthermore, in the
HF diet model, there was a decrease in B cell frequency, and
subsequent PCR analyses revealed a decrease in key transcripts
for early lymphoid commitment, which was likely driven by de-
fects in the bone marrow environment (58). To exemplify, mRNA
levels of IL-7 were lowered, which is important because IL-7 is
secreted by stromal cells in the bone marrow and is a key growth
factor for commitment toward the lymphoid lineage (59). A de-
crease in IL-7 levels would then impair signaling through IL-7Ra
and downstream activation of STAT5 (48). The decrease in plasma
cells could be attributed to the reduction of Blimp1, a transcription
factor necessary for plasma cell generation (51). Alternatively, the
reduction in Blimp1 and other markers that were assayed for in-
termediate B cell development in bone marrow mRNA may
simply reflect the reduction in the frequency of bone marrow
CD19+ cells driven by decreased IL-7Ra signaling.
The hyperstimulation of B cells observed with the HF diet may
be due to several factors. Recent data suggest that circulating leptin,
which is elevated in obesity, may be driving hyperstimulation of
B cells (20). Specifically, B cells from obese individuals have
elevated levels of intracellular TNF-a, which negatively correlates
with their functional capacity (20). Therefore, leptin could be a
potential factor that could be promoting Ab production under
basal conditions from the B cells of obese mice. There could also
FIGURE 7. DHA increases the frequency of bone marrow CD138+ plasma cells in mice consuming a WD. (A) Number of isolated B cells in bone
marrow for mice consuming a control, WD, or WD plus DHA for 15 wk. (B) Percentage and frequency of B cell subsets. (C) Sample flow cytometry data of
long-lived CD138+ plasma cells in bone marrow for mice consuming a control, WD, and WD plus DHA. (D) Percentage and frequency of CD138+ plasma
cells in bone marrow. The results are from 21 d p.i. Data are average 6 SEM; n = 7–8 mice per diet. *p , 0.05, **p , 0.01 by one-way ANOVA followed
by a Bonferroni posttest.
be other factors in obesity, such as elevated fasting insulin or
glucose, that could be influencing Ab production.
A key mechanism that could impair B cell Ab production could
be through the loss of conditional essential fatty acids and thereby
SPMs in obesity. There is evidence demonstrating that obese
children and adults have low levels of circulating essential fatty
acids, including DHA, which could then impair many aspects of
innate and adaptive immunity (30–33, 60). The reduction in DHA
levels in obese subjects could be driven by low consumption of
essential fatty acids in the diet and/or potential genetic modifi-
FIGURE 8. 14-HDHA enhances Ab titers accompanied
by an increase in CD138+ cells upon influenza infection.
(A) HAI and microneutralization titers upon administering
select D-series SPMs 24 h postinfection. (B) HAI and
microneutralization titers upon administering selected D-
series SPMs in parallel with influenza infection. HAI and
microneutralization titers were assayed in (A) and (B) at
14 d p.i. (C) Sample flow cytometry plots of CD138+ cells
on day 21 p.i. for mice treated with 14-HDHA, 17-HDHA,
or PDX. (D) Average percentage and frequency of
CD138+ cells. Data are average 6 SEM; n = 3–5 mice per
treatment. *p , 0.05, **p , 0.01, by unpaired Student t
test.
cations to key enzymes that metabolize DHA (33). We did not
assay for circulating levels of essential fatty acids in this study.
However, we did measure plasma D-series SPM concentration
between lean and obese humans but SPM levels were at the lower
limit of detection (data not shown), which could be due to sample
degradation during the course of the clinical study.
The lipidomic data from the mice consuming the WD showed
that PDX levels were lowered in mice consuming the WD relative
to the control, and RvD2 levels showed a strong trend to be di-
minished compared with the lean control. Suppressed levels of
PDX and other SPMs (which were not probed for such as E-series
SPMs or the PDX isomer PD1) could be driving the inability to
mount effective Ab responses to influenza (61). There is prece-
dence for the lowering of specific SPM precursors and SPMs in
mouse and human obesity in selected adipose tissue depots (62–
64). For instance, the levels of PD1, 14-HDHA, and 17-HDHA are
lowered in adipose tissue of obese mice, relative to controls,
which contributes toward chronic inflammation (62, 65). Fur-
thermore, 14-HDHA and 17-HDHA have also been shown to be
decreased upon wound closure in obese diabetic mice (66).
Therefore, future studies will need to address how lowering of
circulating D-series SPM levels, potentially through a decrease in
DHA levels or in essential fatty acid metabolism, could impair
B cell responses such as class switching and production of Abs.
DHA’s action through SPMs
Ramon et al. (54) demonstrated 17-HDHA boosted Ab production
driven by the production of CD138+ plasma cells in the bone
marrow. Therefore, we investigated whether DHA was enhancing
the production of CD138+ plasma cells and indeed observed a
modest increase in this B cell population. Contrary to our ex-
pectations, when we tested the effects of administering 17-HDHA,
14-HDHA, and PDX during the onset of infection, 14-HDHA
enhanced Ab titers accompanied by an increase in the frequency
of CD138+ cells. However, 14-HDHA, similar to DHA, did not
improve the body weights of the mice after infection. We also
found no effect of DHA on survival upon infection in a prelimi-
nary study (data not shown). This suggests that perhaps the dose of
DHA in the diet or a single injection of 14-HDHA is insufficient to
improve body weights upon infection. Furthermore, DHA may be
enhancing the production of Abs in obese mice without conferring
protection. Indeed, a recent study showed that obese mice, despite
generating neutralizing and nonneutralizing Abs upon adjuvanted
influenza vaccination, failed to be protected upon challenge with
influenza virus (67).
The effects of DHA are probably not just through 14-HDHA.
Given that DHA promoted higher levels of other SPMs, the effects
of DHA are likely driven by a combination of several SPMs, which
may exert their effects at differing time points. This is relevant
given that when 17-HDHA, 14-HDHA, and PDX were adminis-
tered 24 h after the infection, Ab titers were also elevated. Fur-
thermore, the studies with RvD1, RvD2, and PDX showed that all
tested SPMs enhanced HAI titers in a preclinical vaccination
model. Thus, future studies will likely require testing of combi-
nations of SPMs to boost Ab production in obese mice. Addi-
tionally, subsequent experiments using B cell–specific knockouts
and knockdowns of SPM receptors will need to be generated to
establish cause-and-effect of DHA. This will require investigating
whether there are additional B cell SPM receptors besides the ones
analyzed in this study that may be responsive to differing SPMs.
Furthermore, the effects of DHA through SPM production are
likely not just through B cells but may be targeting many other
cell types such as follicular helper T cells that would ultimately
influence Ab production.
Several SPMs generated from DHA may also exert potential
beneficial effects within the lungs where viral transcript levels were
lowered upon infection in the presence of DHA (data not shown).
This was not surprising given a report showing that influenza virus
levels in a mouse model were lowered with PDX (68). Inclusion of
DHA in the diet also promoted robust changes with n-6 PUFA-
derived mediators, particularly in the spleen where arachidonic
acid–derived mediators were lowered. Collectively, the lipidomic
results provide a roadmap for future studies on how selected lipid
mediators from n-6 fatty acids could also target humoral immunity
in obesity. As an example, when PGE2 is knocked down, re-
sponses to influenza infection are improved (69). Therefore, how
DHA and/or SPMs target PGE2 is of relevance given its role in
influenza infection. Thus, the results open the door for screening
additional lipid mediators that may regulate the humoral immune
response (70).
A striking and unexpected finding came from the in vitro ex-
periments with DHA. DHA in culture robustly lowered Ab pro-
duction from B cells, and this finding was consistent with the notion
that DHA is generally immunosuppressive when directly inter-
acting with dendritic cells or helper CD4+ T cells (71, 72). These
results suggest that DHA’s mechanism of action in vivo is not
directly due to DHA acting on the B cells. It is likely that there are
competing effects of DHA and its downstream mediators on B cell
activity. There is literature precedence to show differing effects of
DHA-derived lipid mediators on B cell responses. For instance,
17-HDHA boosts B cell Ab production by promoting the forma-
tion of long-lived plasma cell but dampens differentiation of naive
B cells into IgE-secreting cells (73).
Essential fatty acid status is not well controlled for in
immunometabolism studies
A notable conclusion from these studies is that essential fatty acid
status influences humoral immunity and needs to be controlled for
in mouse and human studies. In fact, various dietary fat sources are
employed in HF diets and typically the fat source is lard in addition
to the use of coconut oil, palm oil, milk fat, and/or soybean oil (74).
Therefore, the use of different fat sources for immunological
studies raises the concern that functional and mechanistic out-
comes could be confounded by variations in the composition of
the fat, such as essential fatty acids, provided to the rodent or
human subject. A recent study even shows differences in immu-
nological outcomes between a low fat diet and mice consuming a
normal mouse chow. Mice consuming a low fat diet were more
susceptible to death from influenza infection compared with mice
on a normal chow (75). Therefore, it is essential to avoid con-
founding results by standardizing treatment regimes in relation-
ship to fat composition.
In conclusion, the results across model systems provide evidence
that B cell cytokine secretion and/or Ab production, outside of the
context of adipose tissue inflammation, are modulated in obesity.
Modifications to B cell function may be a major contributing factor
toward the poor response to infections and vaccinations in the
obese. Furthermore, the data show that essential fatty acid status,
which is dysregulated in obesity, is an important variable in
influencing Ab production in obese mice upon influenza infection,
potentially through an SPM-mediated mechanism. This has im-
plications for further investigating intervention strategies with a
range of essential fatty acids and D-series SPMs for selected
clinical populations such as the obese or even the aged that have
diminished humoral immunity.
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